Incannex says its PSX-001 psilocybin program aligns with the executive order

Incannex Healthcare Inc. (IXHL) — Incannex said its PSX-001 oral synthetic psilocybin program for generalized anxiety disorder fits the executive order's priorities.

The company cited completed Phase 2 results showing a 12.8-point HAM-A anxiety reduction versus 3.6 points for placebo, a 44% clinically meaningful response rate and a 27% remission rate sustained through 11 weeks, with no serious adverse events across 73 patients. Incannex said it holds over $70 million in cash, no debt and an active U.S. IND.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.